NCT01893658View on ClinicalTrials.gov

Xolair (Omalizumab) for Treatment of Drug-induced Acute Tubulointerstitial Nephritis (AIN)

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 1, 2018

Primary Completion Date

September 28, 2018

Study Completion Date

September 28, 2018

Conditions
Acute Interstitial Nephritis
Interventions
DRUG

Omalizumab

administration of a single dose together with the standard treatment

DRUG

Prednisone

standard treatment

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Mayo Clinic

OTHER